PMS Registry
In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system.
Company Name
Title of Study
Update Date
Daiichi Sankyo Taiwan Ltd. Phase IV, non-comparative, open label, multicenter, 28-week switching study of prasugrel maintenance dose from clopidogrel in patients with acute coronary syndrome (ACS) who underwent a percutaneous coronary intervention (PCI) in Taiwan 2018-09-05
Bayer Taiwan Co., Ltd. TAURUS: A MulTinational PhAse IV Study EvalUating “Real World” Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog alfa) for RoUtine ProphylaxiS. 2018-09-05
Bayer Taiwan Co., Ltd. REFINE: Regorafenib observational study in hepatocellular carcinoma 2018-09-05
AbbVie Biopharmaceuticals GmbH Taiwan Branch A Real-world, Prospective, Observational Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST) 2018-09-05
台灣田邊製藥 An open-label study to evaluate clinical efficacy and safety of canagliflozin in the treatment of type 2 diabetes uncontrolled with insulin therapy 2018-09-05
台灣田邊製藥 An open-label study to evaluate clinical efficacy and safety of canagliflozin in the treatment of type 2 diabetes uncontrolled with insulin therapy 2018-09-05
Boehringer Ingelheim Taiwan Non-Interventional study (NIS) Collecting Experiences For IPF in Taiwan 2018-09-05
Boehringer Ingelheim Taiwan Patients’ Assessment of Satisfaction for Stroke Prevention in Atrial FibrillationImpact of Conventional Oral Anticoagulant (OAC) Compared with Novel Oral Anticoagulant (NOAC) 2018-09-05
Takeda Taiwan Safety and Effectiveness of Vedolizumab IV in Real World Clinical Practice in Taiwan: A Registry-Based Study 2018-09-05
Bayer XAMINA / Xarelto® on prevention of stroke and non-central nervous system systeMIc embolism in treatment Naïve Asian patients with non-valvular atrial fibrillation. 2018-09-05
   1 2 3 4 5